CARGO Therapeutics, Inc. (CRGX)

Market Cap	173.52M
Revenue (ttm)	n/a
Net Income (ttm)	-154.14M
Shares Out	46.03M
EPS (ttm)	-4.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	581,071
Open	3.770
Previous Close	3.690
Day's Range	3.670 - 3.830
52-Week Range	3.000 - 33.920
Beta	n/a
Analysts	Hold
Price Target	4.67 (+23.87%)
Earnings Date	Mar 20, 2025

About CRGX

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company’s lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, In...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 10, 2023
• Employees: 116
• Stock Exchange: NASDAQ
• Ticker Symbol: CRGX
• Website: https://cargo-tx.com

Analyst Forecast

According to 7 analysts, the average rating for CRGX stock is "Hold." The 12-month stock price forecast is $4.67, which is an increase of 23.87% from the latest price.

Price Target

$4.67

(23.87% upside)

Analyst Consensus: Hold